Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Keryx Biopharma (KERX) Misses Q1 EPS by 13c
April 28, 2016 8:53 AM EDTKeryx Biopharma (NASDAQ: KERX) reported Q1 EPS of ($0.39), $0.13 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.63 million.
Total operating expenses (excluding cost of goods sold and license expenses) for the first quarter ended March 31, 2016... More
